P-ISSN 2587-2400 | E-ISSN 2587-196X
EJMO. 2021; 5(1): 63-70 | DOI: 10.14744/ejmo.2021.16263

A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients

Abu Taiub Mohammed Mohiuddin Chowdhury1, Mohammad Shahbaz2, Md. Rezaul Karim3, Jahirul Islam4, Guo Dan1, He Shuixiang1
1Department of Gastroenterology, First affiliated hospital of Xi’an Jiaotong University, Xi’an, China, 2Chakoria Upazilla Health Complex, Cox’s Bazar. Bangladesh., 3Biomedical Research Institute of Hubei University of Medicine, Shiyan, China., 4Department of Epidemiology and Healh Statistics; Xi’an Jiaotong University, China,

Objectives: We investigated the outcomes of Ivermectin-Doxycycline vs. Hydroxychloroquine-Azithromycin combination therapy in mild to moderate COVID19 patients. Methods: Patients were divided randomly into two groups: Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for ten days in group A, and Hydroxychloroquine 400mg for the first day, then 200mg BID for nine days + Azithromycin 500mg daily for five days in group B (Control group). RT-PCR for SARS-CoV-2 infection was repeated in all symptomatic patients on the second day onward without symptoms. Repeat PCR was done every two days onward if the result found positive. Time to the negative PCR and symptomatic recovery was measured for each group. Results: All subjects in Group A reached a negative PCR, at a mean of 8.93 days, and reached symptomatic recovery, at a mean of 5.93 days, with 55.10% symptom-free by the fifth day. In group B, 96.36% reached a negative PCR at a mean of 9.33 days and were symptoms-free at 6.99 days. In group A 31.67% of patients expressed symptoms caused by medication, this was 46.43% in group B. Conclusion: The combination therapy of Ivermectin-Doxycycline showed a trend towards superiority to the combination of Hydroxychloroquine-Azithromycin for mild to moderate COVID19 disease. Keywords: Azithromycin, Bangladesh, COVID-19, Doxycycline, Hydroxychloroquine, Ivermectin, randomized controlled trial (RCT)

Cite This Article

Chowdhury A, Shahbaz M, Karim M, Islam J, Dan G, Shuixiang H. A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients. EJMO. 2021; 5(1): 63-70

Corresponding Author: He Shuixiang

Full Text PDF PDF Download